San Francisco-based Trace Neuroscience has launched with $101 million in series A funding to develop ALS therapies focused on ...

Intercept Pharmaceuticals, now wholly owned subsidiary of Italy’s Alfasigma, today revealed that the US Food and Drug ...

The US Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug (IND) application for ...

Germany’s Bayer saw its shares tumble almost 11% to 21.76 euros this morning, as it reported level third-quarter 2024 sales ...

Novel MEK blocker shows promise in rare genetic disorder ...

RAPT Therapeutics has ended its zelnecirnon program following safety concerns raised by the FDA after a severe adverse event ...

Norwegian clinical-stage biotech Nykode Therapeutics revealed that it has received notification from Genentech, a US ...

German life sciences company Merck KGaA (MRK: DE) today announced that the Phase III MANEUVER trial of pimicotinib met its ...

Me is restructuring, cutting 40% of its workforce, ending its therapeutics programs, and refocusing on its consumer genetics ...

While not everything appears rosy in one of AstraZeneca’s (LSE: AZN) major markets, the company has announced a huge ...

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

Anglo-Swedish drugmaker AstraZeneca (LSE: AZN) beat analyst expectations with its third-quarter revenue and earnings figures.